Rubius Therapeutics, a preclinical biotech developing novel therapies based on red blood cells, filed on Friday with the SEC to raise up to $200 million in an initial public offering.
The Cambridge, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol RUBY. Rubius Therapeutics filed confidentially on April 13, 2018. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
